Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma
Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi · 2026
Read Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma by Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13195479.txt.
Description
Shah and a large team report a study from twenty twenty-six on side effects of a two-drug mix for late kidney cancer. The mix pairs a targeted drug with an immune drug as first care. Handling side effects well is key to good results, the authors note. They checked charts for three hundred patients treated in the United States. They also surveyed twenty-five doctors who give this care, most in local clinics.
Most patients started at the standard dose of the targeted drug. Side effects were the top cause of dose cuts and pauses in care. Most stops of either drug came from the disease growing, not from side effects. Most doctors picked the mix chiefly for its survival gains. The study shows how local clinics handle this care.
Catalog record
| CREATOR | Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |